- Home
- GPRO vs SAVA Comparison
GPRO vs SAVA Comparison
Compare GPRO & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRO
- SAVA
- Stock Information
- Founded
- GPRO 2004
- SAVA 1998
- Country
- GPRO United States
- SAVA United States
- Employees
- GPRO N/A
- SAVA N/A
- Industry
- GPRO Industrial Machinery/Components
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- GPRO Consumer Discretionary
- SAVA Health Care
- Exchange
- GPRO Nasdaq
- SAVA Nasdaq
- Market Cap
- GPRO 118.4M
- SAVA 102.4M
- IPO Year
- GPRO 2014
- SAVA N/A
- Fundamental
- Price
- GPRO $1.35
- SAVA $2.34
- Analyst Decision
- GPRO
- SAVA Hold
- Analyst Count
- GPRO 0
- SAVA 1
- Target Price
- GPRO N/A
- SAVA $2.00
- AVG Volume (30 Days)
- GPRO 21.7M
- SAVA 867.7K
- Earning Date
- GPRO 08-11-2025
- SAVA 08-14-2025
- Dividend Yield
- GPRO N/A
- SAVA N/A
- EPS Growth
- GPRO N/A
- SAVA N/A
- EPS
- GPRO N/A
- SAVA N/A
- Revenue
- GPRO $746,731,000.00
- SAVA N/A
- Revenue This Year
- GPRO N/A
- SAVA N/A
- Revenue Next Year
- GPRO $6.79
- SAVA N/A
- P/E Ratio
- GPRO N/A
- SAVA N/A
- Revenue Growth
- GPRO N/A
- SAVA N/A
- 52 Week Low
- GPRO $0.40
- SAVA $1.15
- 52 Week High
- GPRO $2.37
- SAVA $33.98
- Technical
- Relative Strength Index (RSI)
- GPRO 58.88
- SAVA 54.06
- Support Level
- GPRO $1.16
- SAVA $2.20
- Resistance Level
- GPRO $1.36
- SAVA $2.43
- Average True Range (ATR)
- GPRO 0.12
- SAVA 0.17
- MACD
- GPRO -0.02
- SAVA -0.00
- Stochastic Oscillator
- GPRO 59.38
- SAVA 60.42
About GPRO GoPro Inc.
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.